News

US FDA approves Nuvation Bio's rare lung cancer drug
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...
US FDA approves Nuvation Bio's lung cancer therapy
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of ...
Nuvation Bio: Judgement Day Grows Closer
Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...
Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi
Nuvation Bio (NUVB) wins U.S. FDA approval for its oral antitumor agent Ibtrozi as a treatment for certain patients with ...
Business Wire2d
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lun…
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer ...
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval
FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing ...
The Pharma Letter1d
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC
The US Food and Drug Administration (FDA) yesterday approved Nuvation Bio’s (NYSE: NUVB) Ibtrozi (taletrectinib), a kinase ...
Contract Pharma1d
U.S. FDA Approves Nuvation Bio’s Ibtrozi
Nuvation Bio Inc., a global oncology company, received U.S. Food and Drug Administration (FDA) approval of Ibtrozi ...
pharmaphorum1d
FDA clears Nuvation's first product Ibtrozi, for lung cancer
Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...
PMLive1d
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer
The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...
Investing2d
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib
NEW YORK - The U.S. Food and Drug Administration has approved Nuvation Bio Inc.’s (NYSE: NUVB) IBTROZI (taletrectinib) for adult patients with locally advanced or metastatic ROS1-positive non ...